RNS Reminder20 Jun 2020 00:08
Tue, 9th Jun 2020 07:00
RNS Number : 3255P
Omega Diagnostics Group PLC
09 June 2020
New MTA covering additional Mologic COVID-19 tests
In addition, Omega announces it has widened its collaboration with Mologic by signing another Material Transfer Agreement ("MTA"), providing the Company with access to raw materials and know-how to manufacture the following additional Mologic COVID-19 tests:
· an ELISA antigen test that determines the concentration of COVID-19 (SARS-CoV-2) antigens in human blood, saliva or swab extract sample thereby identifying an individual with an active COVID-19 infection
· a lateral flow antigen test product that determines the concentration of COVID-19 (SARS-CoV-2) antigens in a human blood, saliva, or swab extract sample also used to identify an individual with an infection
· a lateral flow antibody test product that determines the concentration of human antibodies in a human blood sample specifically targeting the COVID-19 (SARS-CoV-2) antigens
Omega is now involved with five opportunities relating to COVID-19 testing, of which four utilise Mologic's technology platforms, including the COVID-19 ELISA which the Company is already shipping. Two are ELISA (lab based) tests, both antigen and antibody, and three are lateral flow tests. Two of the lateral flow tests are in collaboration with Mologic and the third is an antibody test with UK Rapid Test Consortium as originally announced on 9 April 2020.
Lateral flow (POC) antigen, and antibodies test are huge game changers, and will help get the economy back on it's feet and reopen schools.. The last sentence is the most powerful. Surely DF next week.